- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04838041
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
April 2, 2024 updated by: Ehab L Atallah, Medical College of Wisconsin
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51.
All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI).
All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.
Study Overview
Status
Recruiting
Conditions
Detailed Description
All eligible patients will begin asciminib in combination with a TKI on cycle 1 day 1 of the combination phase.
They will continue combination therapy for a total of 12 cycles (minimum of 12 months).
Each cycle will be ~28 days.
At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase.
Once in the TFR phase, patients will also discontinue their TKI and be monitored off treatment.
The primary endpoint of this study is the 12-month 'second' TFR rate after completion of 12 cycles of combination therapy.
Patients will remain in the TFR phase of the study for up to three years and will have central PCR testing during the first two years.
Therefore, the total duration of the subject participation trial will be approximately five years (one year on combination treatment phase plus three years in the TFR phase plus one year of long-term follow-up post TFR or early discontinuation.
Study Type
Interventional
Enrollment (Estimated)
51
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ehab Atallah, MD
- Phone Number: 414-805-4600
- Email: eatallah@mcw.edu
Study Contact Backup
- Name: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Phone Number: 414-805-8900
- Email: cccto@mcw.edu
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- The Barbara Ann Karmanos Cancer Institute
-
Contact:
- Sharon Prokop
- Phone Number: 313-576-9363
- Email: prokops@karmanos.org
-
Principal Investigator:
- Jay Yang, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Michael Mauro, MD
- Email: maurom@mskcc.org
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute
-
Contact:
- Srinivas Tantravahi, MBBS
- Email: Srinivas.Tantravahi@hci.utah.edu
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert Hospital & the Medical College of Wisconsin
-
Contact:
- Ehab Atallah, MD
- Phone Number: 414-805-4600
- Email: eatallah@mcw.edu
-
Principal Investigator:
- Ehab Atallah, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years old.
- Willing and able to give informed consent.
- Diagnosed with chronic myelogenous leukemia (CML) in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR::ABL1 protein. Subtype classification whether b3a2 (e14a2) or b2a2 (e13a2) is not required for study eligibility.
- Must have a documented history of attempting only one prior TKI discontinuation under the guidance of a treating physician. TKI includes dasatinib, imatinib or nilotinib.
Must have met all the following criteria prior to first attempt to discontinue their TKI:
- Stable molecular response (MR4; < 0.01% IS) for > 2 years (with allowance for a two-week variance), as documented on at least four tests, performed at least three months apart (e.g., If a patient has had >4 PCR tests performed during the two years leading up to their initial TKI discontinuation, any value between 0.01 and 0.05% IS is considered a stable result, however, at least four tests must be < 0.01% IS. If any results are >0.05% IS, tests must have been repeated within one month and be less than 0.01% IS and stable.
- Treatment with one of the following FDA approved TKIs; imatinib, dasatinib, nilotinib at any dose for a minimum of approximately three years (allowance of a four-week variance) prior to discontinuing TKIs.
- Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed).
- Must have relapsed (defined as loss of major molecular response (MMR), RQ-PCR for BCR::ABL1 >0.1% IS after first attempted TKI discontinuation.
- After first failed TFR attempt, must have a minimum duration of one year of retreatment with TKI, and must plan to remain on that TKI for a minimum of 12 months during the combination treatment phase.
- Current TKI must be the same as the TKI being taken prior to the initial TFR attempt (e.g., if patient is on imatinib prior to first TFR attempt, they should be on imatinib at time of enrollment on this study).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Must have a RQ-PCR for BCR::ABL1 < 0.0032% IS (MR4.5) reported by the trial designated central lab at the time of study enrollment.
- Lipase ≤ 1.5 x upper limit of normal (ULN). For lipase > ULN - ≤ 1.5 x ULN, value should be considered not clinically significant and not associated with risk factors for acute pancreatitis.
Female patients must meet one of the following:
- Postmenopausal for at least one year before the screening visit,
- Surgically sterile
- If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through 90 days after the last dose of study drug,
- Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:
- Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose.
- Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable.
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
Exclusion Criteria:
- History of accelerated or blast phase CML.
- A second malignancy requiring active treatment.
- History of recent (within 12 months) acute pancreatitis or chronic pancreatitis.
- Subjects who have previously received treatment with asciminib.
- Subjects with platelet (PLT) count < 100 × 109/L or an absolute neutrophil count (ANC) of < 1 × 109/L or hemoglobin < 8 g/dL.
- Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≥3 times the institutional upper limit of normal.
- Creatinine clearance < 40 mL/min.
- Total bilirubin ≥ 1.5 times the institutional upper limit of normal (unless direct bilirubin is within normal limits).
- Pregnant or lactating.
- Unable to comply with lab appointment schedule and patient-reported outcome (PRO) assessments.
- Another investigational drug within four weeks of enrollment.
- Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol.
- Patient has undergone a prior allogeneic stem cell transplant.
- Screening 12-lead electrocardiogram (ECG) showing a baseline corrected QT interval >480msec (patients with a pacemaker will still be eligible with QTc>500msec).
- Known active hepatitis B infection.
Eligibility for TFR Phase:
- Stable molecular response (MR4.5; < 0.0032% IS) documented on at least three tests (may include TFR phase screening PCR) by the trial designated lab, performed approximately three months apart while on combination phase.
- TFR phase screening PCR RQ-PCR for BCR::ABL1 < 0.0032% IS (MR4.5) by the trial designated lab.
- ECOG 0-3.
- Completion of 12 cycles on the combination therapy phase.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Asciminib 40 mg PO daily plus imatinib (maximum dose of 400 mg PO once daily)
All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase.
They will continue combination therapy for a total of 12 cycles (minimum of 12 months).
At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase.
Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
|
40 mg by mouth (PO) when used with imatinib.
Other Names:
Maximum dose of 400 mg PO once daily.
Other Names:
|
Experimental: Asciminib 40 mg twice daily plus nilotinib (maximum dose of 300 mg twice daily)
All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase.
They will continue combination therapy for a total of 12 cycles (minimum of 12 months).
At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase.
Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
|
40 mg twice daily when used with nilotinib.
Other Names:
Maximum dose of 300 mg twice daily.
Other Names:
|
Experimental: Asciminib 80 mg daily plus dasatinib (maximum dose of 100 mg PO once daily)
All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase.
They will continue combination therapy for a total of 12 cycles (minimum of 12 months).
At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase.
Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
|
80 mg daily when used with dasatinib.
Other Names:
Maximum dose of 100 mg PO once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
One-year "second" treatment-free remission.
Time Frame: 1 year
|
This will be measured by the number of subjects who achieve one-year treatment-free remission after 12 months of combination therapy with TKI plus asciminib.
These subjects have previously failed a first treatment free remission attempt.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center
- Principal Investigator: Ehab Atallah, MD, Medical College of Wisconsin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2021
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
July 1, 2029
Study Registration Dates
First Submitted
March 26, 2021
First Submitted That Met QC Criteria
April 6, 2021
First Posted (Actual)
April 8, 2021
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Micronutrients
- Protein Kinase Inhibitors
- Vitamins
- Vitamin B Complex
- Tyrosine Kinase Inhibitors
- Imatinib Mesylate
- Dasatinib
- Niacinamide
- Nilotinib
- Asciminib
Other Study ID Numbers
- PRO00040685
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Phase Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Children's Oncology GroupPfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...Active, not recruitingAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CMLUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
The University of Hong KongUnknownCessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaLeukemia, Myelogenous, Chronic PhaseHong Kong
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
Clinical Trials on Asciminib 40 MG
-
University of JenaNovartis Pharmaceuticals; Ludwig-Maximilians - University of MunichActive, not recruiting
-
Genencell Co. Ltd.Recruiting
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
Grupo Español de Tumores Huérfanos e InfrecuentesAstellas Pharma Inc; Apices Soluciones S.L.Completed
-
Janssen Research & Development, LLCCompleted
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaboratorsNot yet recruitingHepatocellular Carcinoma
-
SandozCompletedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
-
Vigonvita Life SciencesCompleted
-
AstraZenecaActive, not recruitingStage IB-IIIA Non-small Cell Lung CarcinomaUnited States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
-
Novartis PharmaceuticalsCompletedRenal ImpairmentGermany, Bulgaria